A novel approach to optimize and formulate fast disintegrating tablets for nausea and vomiting.
The aim of this study was to optimize and formulate fast disintegrating tablets (FDTs) for nausea and vomiting using aminoacetic acid, carmellose and sodium alginate with enough mechanical strength. Ondansetron HCl (water soluble) or domperidone (water insoluble) drug were added to FDTs and their disintegration behaviour was evaluated. Plackett Burman Screening Design was used to screen the independent active process variables [concentration of aminoacetic acid (X (1)), concentration of carmellose (X (2)) and tablet crushing strength (X (3))] which were found to actively influence the dependent variables [disintegration time in the mouth (DT), wetting time (WT), and water absorption ratio (WAR)] for both the drugs. Also, the coefficients of active variables (DT, WT and WAR) of FDTs containing domperidone was found to be significantly different (P < 0.05) from the coefficients of active factors (X (1), X (2) and X (3)) containing ondansetron HCl FDTs. Further, FDTs containing domperidone was prepared according to central composite design for estimating the effect of active factors (X (1), X (2), X (3)) in extended spherical domain. The regression analysis of quadratic fit revealed that DT, WT and WAR were 98% correlated with active factors (X (1), X (2) or X (3)). The optimized domperidone FDTs were further compared with superdisintegrants (croscarmellose sodium or crospovidone). The data revealed that optimized domperidone FDTs were better than domperidone FDTs containing croscarmellose or crospovidone. Hence, this novel excipients combination can be used for delivery of water insoluble drugs in place of superdisintegrants.
Goel
Honey
H
Pharmaceutics Division, Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, India.
Vora
Nishant
N
Rana
Vikas
V
D000293:Adolescent; D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage / Q000138:chemical synthesis / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D009055:Mouth / Q000187:drug effects / Q000378:metabolism; D009325:Nausea / Q000188:drug therapy* / Q000378:metabolism; D012995:Solubility / Q000187:drug effects; D013607:Tablets / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000493:pharmacokinetics; D013997:Time Factors; D014839:Vomiting / Q000188:drug therapy* / Q000378:metabolism; D055815:Young Adult
D000932:Antiemetics; D013607:Tablets